Wilding G - Search Results

1

A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.

Holen K, DiPaola R, Liu G, Tan AR, Wilding G, Hsu K, Agrawal N, Chen C, Xue L, Rosenberg E, Stein M. Holen K, et al. Among authors: wilding g. Invest New Drugs. 2012 Jun;30(3):1088-95. doi: 10.1007/s10637-011-9653-1. Epub 2011 Mar 22. Invest New Drugs. 2012. PMID: 21424701 Free PMC article. Clinical Trial.

2

Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days.

Bailey H, Kohler P, Tuttle R, Carbone PP, Hohneker JA, Clendeninn NJ, Wilding G. Bailey H, et al. Among authors: wilding g. Invest New Drugs. 1992 Nov;10(4):279-87. doi: 10.1007/BF00944182. Invest New Drugs. 1992. PMID: 1487401 Clinical Trial.

3

A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.

Bailey H, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Grem JL, Spriggs DR. Bailey H, et al. Among authors: wilding g. Cancer Chemother Pharmacol. 1992;30(4):297-302. doi: 10.1007/BF00686299. Cancer Chemother Pharmacol. 1992. PMID: 1643698 Clinical Trial.

4

Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.

Bailey H, Tutsch KD, Arzoomanian RZ, Tombes MB, Alberti D, Bruggink J, Wilding G. Bailey H, et al. Among authors: wilding g. Cancer Res. 1991 Feb 15;51(4):1105-8. Cancer Res. 1991. PMID: 1705165 Clinical Trial.

5

A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma.

Berlin J, King AC, Tutsch K, Findlay JW, Kohler P, Collier M, Clendeninn NJ, Wilding G. Berlin J, et al. Among authors: wilding g. Invest New Drugs. 1994;12(2):137-41. doi: 10.1007/BF00874444. Invest New Drugs. 1994. PMID: 7860231 Clinical Trial.

6

Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer.

Wilding G, Grindey G, Munshi N, Seitz D, Einhorn L. Wilding G, et al. Invest New Drugs. 1993 May-Aug;11(2-3):203-5. doi: 10.1007/BF00874156. Invest New Drugs. 1993. PMID: 8262732 Clinical Trial. No abstract available.

7

Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor.

Berlin J, Tutsch KD, Hutson P, Cleary J, Rago RP, Arzoomanian RZ, Alberti D, Feierabend C, Wilding G. Berlin J, et al. Among authors: wilding g. J Clin Oncol. 1997 Feb;15(2):781-9. doi: 10.1200/JCO.1997.15.2.781. J Clin Oncol. 1997. PMID: 9053505 Clinical Trial.

8

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder.

Khorsand M, Lange J, Feun L, Clendeninn NJ, Collier M, Wilding G. Khorsand M, et al. Among authors: wilding g. Invest New Drugs. 1997;15(2):157-63. doi: 10.1023/a:1005860806635. Invest New Drugs. 1997. PMID: 9220296 Clinical Trial.

9

Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin.

Hutson PR, Tutsch KD, Rago R, Arzoomanian R, Alberti D, Pomplun M, Church D, Marnocha R, Cheng AL, Kehrli N, Wilding G. Hutson PR, et al. Among authors: wilding g. Clin Cancer Res. 1998 Jun;4(6):1429-36. Clin Cancer Res. 1998. PMID: 9626459 Clinical Trial.

10

A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors.

Berlin JD, Alberti DB, Arzoomanian RZ, Feierabend CA, Simon KJ, Binger KA, Marnocha RM, Wilding G. Berlin JD, et al. Among authors: wilding g. Invest New Drugs. 1998-1999;16(4):325-30. doi: 10.1023/a:1006242005837. Invest New Drugs. 1998. PMID: 10426665 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

550 results

Search Page

Filters